CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation as proximal driver in CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

Target: CCL2-CCR2 Composite Score: 0.626 Price: $0.63 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
6
Citations
1
Debates
6
Supporting
1
Opposing
Quality Report Card click to collapse
B
Composite: 0.626
Top 35% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.70 Top 35%
B Evidence Strength 15% 0.62 Top 34%
B+ Novelty 12% 0.72 Top 37%
B Feasibility 12% 0.67 Top 44%
B Impact 12% 0.64 Top 65%
C+ Druggability 10% 0.54 Top 55%
C+ Safety Profile 8% 0.52 Top 54%
C+ Competition 6% 0.58 Top 62%
B Data Availability 5% 0.66 Top 44%
B Reproducibility 5% 0.61 Top 44%
Evidence
6 supporting | 1 opposing
Citation quality: 0%
Debates
1 session B
Avg quality: 0.67
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

How does the CCL2-CCR2 chemokine axis at the neuromuscular junction drive selective vulnerability of fast-fatigable motor neurons over slow-resistant motor neurons in ALS, and does blocking CCR2 signalling in myeloid cells reverse NMJ denervation in a cell-type-specific manner in ALS mouse models?

→ View full analysis & debate transcript

Description

CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation should produce a measurable proximal phenotype before late disease pathology. The decisive test is myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["CCL2 Chemokine Secretion
Denervated Muscle and Schwann Cells"] B["CCR2 Receptor Upregulation
Pro-inflammatory Macrophages"] C["CX3CR1/CCR2 Monocyte Recruitment
NMJ Neuromuscular Junction"] D["Fast-Fatigable Motor Neuron
Synapse Stripping Begins"] E[" neuromuscular Dependency
Sustained Jnk/c-Jun Signaling"] F["Denervation and Axonal Degeneration
ALS Disease Progression"] A --> B B --> C C --> D D --> E E --> F style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7 style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.70 (15%) Evidence 0.62 (15%) Novelty 0.72 (12%) Feasibility 0.67 (12%) Impact 0.64 (12%) Druggability 0.54 (10%) Safety 0.52 (8%) Competition 0.58 (6%) Data Avail. 0.66 (5%) Reproducible 0.61 (5%) KG Connect 0.50 (8%) 0.626 composite
7 citations 5 with PMID 5 medium Validation: 0% 6 supporting / 1 opposing
For (6)
5
No opposing evidence
(1) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
2
1
MECH 4CLIN 2GENE 1EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
MCP1-CCR2 and neuroinflammation in the ALS motor c…SupportingMECHJ Neuroinflamma… MEDIUM2019-PMID:31666087-
The CCL2-CCR2 axis drives neuromuscular denervatio…SupportingMECHNat Commun MEDIUM2025-PMID:40750607-
Vascular endothelial growth factor-A (VEGF-A) and …SupportingCLINJ Neuroinflamma… MEDIUM2011-PMID:21569455-
CCR2 is localized in microglia and neurons, as wel…SupportingGENEMol Brain MEDIUM2020-PMID:32349774-
Possible association between expression of chemoki…SupportingCLINPLoS One MEDIUM2012-PMID:22685564-
Study demonstrated CCL2-CCR2 drives NMJ denervatio…SupportingMECHThe CCL2-CCR2 a…-----
CCR2 blockade may reduce inflammation without dire…OpposingMECHThe CCL2-CCR2 a…-----
Legacy Card View — expandable citation cards

Supporting Evidence 6

Study demonstrated CCL2-CCR2 drives NMJ denervation in ALS but noted that the mechanism of selective fast vs. …
Study demonstrated CCL2-CCR2 drives NMJ denervation in ALS but noted that the mechanism of selective fast vs. slow motor neuron vulnerability downstream of this axis was not resolved.
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis
MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. MEDIUM
J Neuroinflammation · 2019 · PMID:31666087
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis. MEDIUM
Nat Commun · 2025 · PMID:40750607
Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (… MEDIUM
Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients.
J Neuroinflammation · 2011 · PMID:21569455
CCR2 is localized in microglia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of AL… MEDIUM
CCR2 is localized in microglia and neurons, as well as infiltrating monocytes, in the lumbar spinal cord of ALS mice.
Mol Brain · 2020 · PMID:32349774
Possible association between expression of chemokine receptor-2 (CCR2) and amyotrophic lateral sclerosis (ALS)… MEDIUM
Possible association between expression of chemokine receptor-2 (CCR2) and amyotrophic lateral sclerosis (ALS) patients of North India.
PLoS One · 2012 · PMID:22685564

Opposing Evidence 1

CCR2 blockade may reduce inflammation without directly rescuing vulnerable motor-neuron physiology
The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-28 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Theorist position for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

Source basis: The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (Nature Communications, 2025, DOI 10.1038/s41467-025-62351-3). The stored gap context says: Study demonstrated CCL2-CCR2 drives NMJ denervation in ALS but noted that the mechanism of selective fast vs. slow motor neuron vulnerability downstream of this axis was not resolved.

Primary hypothesis: CCL2-CCR2 myeloid signaling as a selective driver of f

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Skeptic critique for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: CCR2 blockade may reduce inflammation without directly rescuing vulnerable motor-neuron physiology.

The debate shou

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Domain expert assessment for analysis f7f8019f-08f6-428b-adff-85e8ea202b60: CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation as proximal driver in CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS",
"description": "CCL2-CCR2 myeloid signaling as a selective driver of fast-fatigable motor-neuron denervation should produce a measurable proximal phenotype before late disease pathology. The decisive test is myeloid-specific CCR2 blockade with fast/slow motor-unit stratification and NMJ integrity measurements.",
"target_gene": "CCL2-CCR2",

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (5)

No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
6

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.676

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for CCL2-CCR2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CCL2-CCR2 →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 CCL2-CCR2 — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for CCL2-CCR2 structures...
Querying Protein Data Bank API

Source Analysis

CCL2-CCR2 Axis at NMJ: Mechanism of Selective Motor Neuron Vulnerability in ALS

neurodegeneration | 2026-04-27 | open

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (3)

CCL2-CCR2 Driven Macrophage Infiltration Selectively Strips Fast-Fatig
Score: 0.68 · CCL2
Cell-state stratification is required to resolve CCL2-CCR2 Axis at NMJ
Score: 0.61 · NMJ
Perturbation-first validation should precede therapeutic claims for CC
Score: 0.61 · ALS
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.